ATE544848T1 - Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais) - Google Patents

Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)

Info

Publication number
ATE544848T1
ATE544848T1 AT06837280T AT06837280T ATE544848T1 AT E544848 T1 ATE544848 T1 AT E544848T1 AT 06837280 T AT06837280 T AT 06837280T AT 06837280 T AT06837280 T AT 06837280T AT E544848 T1 ATE544848 T1 AT E544848T1
Authority
AT
Austria
Prior art keywords
immune system
artificial immune
cocultural
ais
lte
Prior art date
Application number
AT06837280T
Other languages
English (en)
Inventor
William Warren
Donald Drake Iii
Janice Moser
Inderpal Singh
Haifeng Song
Eric Mishkin
Original Assignee
Sanofi Pasteur Vaxdesign Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Vaxdesign Corp filed Critical Sanofi Pasteur Vaxdesign Corp
Application granted granted Critical
Publication of ATE544848T1 publication Critical patent/ATE544848T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2535/00—Supports or coatings for cell culture characterised by topography
    • C12N2535/10—Patterned coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06837280T 2006-06-15 2006-11-08 Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais) ATE544848T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/453,046 US8071373B2 (en) 2004-04-28 2006-06-15 Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
PCT/US2006/043712 WO2007145658A1 (en) 2006-06-15 2006-11-08 Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)

Publications (1)

Publication Number Publication Date
ATE544848T1 true ATE544848T1 (de) 2012-02-15

Family

ID=38659381

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06837280T ATE544848T1 (de) 2006-06-15 2006-11-08 Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)

Country Status (6)

Country Link
US (3) US8071373B2 (de)
EP (4) EP2410045B1 (de)
AT (1) ATE544848T1 (de)
CA (3) CA2836760C (de)
IL (4) IL195798A (de)
WO (2) WO2007145658A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7785883B2 (en) 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7785806B2 (en) 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
WO2007075979A2 (en) 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
US20070178076A1 (en) * 2005-12-21 2007-08-02 Drake Donald Iii Porous membrane device that promotes the differentiation of monocytes into dendritic cells
EP2021460A4 (de) * 2006-05-11 2010-11-17 Univ Maryland Biotech Inst Allgemeines verfahren zur erzeugung menschlicher antikörperreaktionen in vitro
EP2409715A1 (de) * 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
EP2260097B1 (de) * 2008-03-12 2017-04-26 Sanofi Pasteur VaxDesign Corporation Einbeziehung eines krankheitsmodells in ein artifizielles immunsystem (ais)
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US10222373B2 (en) 2016-02-29 2019-03-05 Rarecyte, Inc. Method to identify antigen-specific immune cells
AU2017298298B2 (en) 2016-07-18 2024-03-07 President And Fellows Of Harvard College Human lymphoid tissue-on-chip
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021186278A1 (en) * 2020-03-20 2021-09-23 Immunitybio, Inc. T cells that respond to patient neoepitopes
US20250180543A1 (en) * 2022-03-08 2025-06-05 Whitehead Institute For Biomedical Research Compositions and methods of a high-throughput screen to identify compounds that alter macrophage-mediated cytotoxicity of target cells
WO2026035682A1 (en) * 2024-08-05 2026-02-12 Amgen Inc. Lymphoid cell compositions, systems, and assays

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160490A (en) * 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US5266480A (en) 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
JPH0310674A (ja) 1989-06-09 1991-01-18 Terumo Corp 細胞培養用多孔質膜およびそれを用いた細胞培養器
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5695996A (en) * 1994-09-23 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Artificial organ culture system
JP3452366B2 (ja) 1995-10-20 2003-09-29 トランスティッシュウ テクノロジーズ ゲーエムベーハー 新規人工組織、その製法およびその使用
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5739001A (en) * 1996-10-29 1998-04-14 E. I. Du Pont De Nemours And Company Solid phase cell-based assay
US6177282B1 (en) * 1997-08-12 2001-01-23 Mcintyre John A. Antigens embedded in thermoplastic
JP3593032B2 (ja) 1997-09-10 2004-11-24 純一 益山 ヒト単核球に対するモノクローナル抗体
CN1272878A (zh) 1997-09-25 2000-11-08 基质细胞有限责任公司 造血祖细胞长时培养的方法和设备
DE69840739D1 (de) * 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
AU2797799A (en) 1998-02-27 1999-09-15 Anticancer, Inc. (in vitro) model for viral infection and immune response
EP1066531A1 (de) 1998-03-25 2001-01-10 OSTERGAARD, Steen Mikrosystem und verfahren zur manipulation von partikeln mittels feldern
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
RU2002112751A (ru) 1999-11-12 2004-02-27 Файброджен, Инк. (Us) Рекомбинантные желатины
CN1423523A (zh) * 1999-11-17 2003-06-11 罗切斯特大学 来自人体内的免疫系统
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US20050164388A1 (en) * 2001-02-07 2005-07-28 Young-Sook Son Method of isolating epithelial cells, method of preconditioning cells, and methods of preparing bioartificial skin and dermis with the epithelial cells and preconditioned cells
WO2003026712A1 (en) * 2001-09-25 2003-04-03 Japan Science And Technology Agency Method of preparing basement membrane, method of constructing basement membrane specimen, reconstituted artificial tissue using the basement membrane specimen and process for producing the same
US20030166274A1 (en) 2001-11-15 2003-09-04 Hewitt Charles W. Three-dimensional matrix for producing living tissue equivalents
FR2833271B1 (fr) 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
IL164661A0 (en) * 2002-03-18 2005-12-18 Vaxdesign Corp Dentritic cell nodes
US7476514B2 (en) * 2002-04-11 2009-01-13 Cylex, Inc. Method for monitoring the immune response and predicting clinical outcomes in transplant recipients
US20040009943A1 (en) 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
AU2003275421A1 (en) 2002-10-03 2004-04-23 Andrea Bottaro Three-dimensional peripheral lymphoid organ cell cultures
US20040109876A1 (en) 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
JP4460908B2 (ja) 2003-03-07 2010-05-12 パイロットインキ株式会社 可逆変色性玩具
EP1479760A1 (de) 2003-05-19 2004-11-24 ProBioGen AG Künstliches Immunorgan
US20050053667A1 (en) 2003-07-09 2005-03-10 Darrell Irvine Programmed immune responses using a vaccination node
CA2548992A1 (en) 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US20070141552A1 (en) * 2004-04-28 2007-06-21 Warren William L Automatable artificial immune system (AIS)
JP5795699B2 (ja) 2004-04-28 2015-10-14 サノフィ パスツール ヴァックスデザイン コーポレーション 人工免疫システム：作製および使用方法
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US20060275270A1 (en) * 2004-04-28 2006-12-07 Warren William L In vitro mucosal tissue equivalent
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7709256B2 (en) 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
EP1970444A4 (de) 2005-12-12 2010-01-20 Riken Verfahren zur herstellung eines antigenspezifischen hybridoms unter verwendung eines künstlichen lymphknotens mit guter effizienz
US20070178076A1 (en) * 2005-12-21 2007-08-02 Drake Donald Iii Porous membrane device that promotes the differentiation of monocytes into dendritic cells
WO2007075979A2 (en) 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
EP2409715A1 (de) * 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
CA2692689A1 (en) * 2007-07-06 2009-01-15 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens
GB2512355B (en) 2013-03-27 2016-06-01 Warwick Tim Infused additive manufactured objects

Also Published As

Publication number Publication date
EP2410045A1 (de) 2012-01-25
EP2410045B1 (de) 2013-08-28
IL218447A0 (en) 2012-04-30
CA2836760A1 (en) 2007-12-21
CA2836760C (en) 2015-07-14
IL195895A0 (en) 2011-08-01
EP2032693B1 (de) 2012-02-08
EP2041271B1 (de) 2012-05-16
IL213519A0 (en) 2011-07-31
WO2007146334A9 (en) 2008-03-13
CA2655405A1 (en) 2007-12-21
EP2032693A1 (de) 2009-03-11
EP2570477B1 (de) 2016-01-06
WO2007145658A1 (en) 2007-12-21
CA2659676A1 (en) 2007-12-21
US8962319B2 (en) 2015-02-24
US8071373B2 (en) 2011-12-06
EP2041271A2 (de) 2009-04-01
US20070154956A1 (en) 2007-07-05
CA2659676C (en) 2015-03-24
US20120052517A1 (en) 2012-03-01
WO2007146334A3 (en) 2008-04-24
US8697371B2 (en) 2014-04-15
US20140248640A1 (en) 2014-09-04
IL195895A (en) 2013-01-31
AU2006344474A1 (en) 2007-12-21
IL195798A (en) 2013-02-28
IL195798A0 (en) 2011-08-01
CA2655405C (en) 2016-06-07
EP2570477A1 (de) 2013-03-20
WO2007146334A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
WO2007146267A3 (en) Disease model incorporation into an artificial immune system (ais)
WO2008073635A3 (en) Automatable artificial immune system (ais)
WO2007108835A3 (en) Automatable artificial immune system (ais)
MX389827B (es) Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21).
CO6491042A2 (es) Produccion de titulos elevados de poliovirus para la produccion de vacunas
WO2005104755A3 (en) Artificial immune system: methods for making and use
EP2588592A4 (de) Verwendung von perfusions-dezellularisierten organen für abgeglichene rezellularisierung
BRPI0915915A2 (pt) vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas
DK2274419T3 (da) Fremgangsmåder til fremstilling af hårmikrofollikler og de novopapiller og anvendelse heraf til in vitro-test og in vivo-implantationer
EP2224921A4 (de) Modulation der immunantwort
CL2011003091A1 (es) Composicion que comprende conjugado covalente entre hemoglobina funcional y nativa y al menos una molecula de polietilenglicol; metodo para preparar composicion; uso de dicha composicion para producir medicina de transfusion.
MX2016004575A (es) Metodos de modificacion de celulas huespedes.
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
BR112015021993A8 (pt) polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
BR112014019328A8 (pt) Perfil de fenótipo de células progenitoras retinais humanas
WO2014027176A3 (en) Stem cell culture method
PL1951300T3 (pl) Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
ES2479543T1 (es) Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas
BR112012033727A2 (pt) células semelhantes a tr1 de produção de il-13 e uso das mesmas
MX2021013005A (es) Metodos de fabricacion de celulas car-t alogenicas.